<DOC>
	<DOCNO>NCT00116259</DOCNO>
	<brief_summary>There scarcity clinical trial assess effect medication child bipolar disorder . This study aim assess efficacy Aripiprazole ( novel anti-psychotic drug ) treatment child adolescent bipolar disorder comorbid ADHD . The study design 8-week randomized , double blind , parallel group trial . Patients randomize either aripiprazole placebo . The main hypothesis : 1 . Aripiprazole significantly reduce maniac score compare placebo 2 . Aripiprazole significantly reduce ADHD score compare placebo</brief_summary>
	<brief_title>Aripiprazole Children Adolescents With Bipolar Disorder Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>Bipolar disorder ( BD ) chronic disorder severely affect normal development child adolescent . The disorder associate high rate suicide tentative high-risk behavior like sexual promiscuity drug abuse . Bipolar disorder child also associate high rate comorbidity , especially Attention-Deficit Hyperactivity Disorder ( ADHD ) . There scarcity clinical trial assess effect medication child BD . Moreover , frequent presence comorbid ADHD might determine low response treatment . Aripiprazole novel anti-psychotic drug . Its mechanism action seem related stabilization dopaminergic transmission , act partial agonist especially dopaminergic D2 receptor . It also effect 5-HT1a serotonergic receptor . Thus , might promise effect child adolescent comorbid BD ADHD . A retrospective chart review , recently publish , suggest efficacy drug child BD . This study aim assess efficacy Aripiprazole ( novel anti-psychotic drug ) treatment 50 child adolescent ( age range : 08 17 years-old ) Bipolar Disorder comorbid ADHD . The study design 6-week randomized , double blind , parallel group trial . Patients randomize either aripiprazole placebo . The hypothesis : 1 ) Aripiprazole significantly reduce maniac score compare placebo ; 2 ) Aripiprazole significantly reduce ADHD score compare placebo ; 3 ) Aripiprazole significantly associate weight gain compare placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Age : 817 BD type I II comorbid ADHD Baseline score YMRS &gt; = 20 IQ &lt; 70 Pharmacologic treatment last month Pregnancy absence contraceptive method fertile girl Diagnoses : pervasive development disorder , schizophrenia , drug abuse dependency Risk suicide homicide Clinical condition might interfere study Known sensibility aripiprazole</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>clinical trial</keyword>
	<keyword>aripiprazole</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Attention-Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
</DOC>